Created projects

Live projects

No projects found.

Draft projects

No projects found.

Pending Projects

No projects found.

Membership Projects

No projects found.

Suspended Projects

No projects found.

Expired Projects

    No projects found.

view all

You are logged in as Log out

Needle-free injector for all: A life free of needles

by Dan Cohen

Finally - any subcutaneous drug, any patient, without pain, scarring, infections, anxiety, or dangerous waste.
Irvine, CA United States Medical Device Diabetes Patient Power Tools! MedStartr Ventures challenge

All Team Company Patients Physicians Hospital Partners Mission Innovation Details Supporters Comments Updates

About our project

The problem we solve: Nobody likes needles. Patients stay away from procedures due to fear and anxiety. Injection complications are frequent and costly. Needlestick injuries cost the medical system hundreds of millions. There's no need for any of it, anymore.

About our solution: We have an FDA approved, easy to use self-administration tool for any liquid subcutaneous medication. Completely pain free, causes no scarring, generates no dangerous waste, and anybody can learn to use it on themselves without fear. Economically competitive with safe needle technologies but reduces anxiety, increases patient compliance, and carries benefits for practitioners and hospitals.

Progress to date:

We are manufacturing the new products already. The devices were previously in the market and we have restored them. All animal testing, clinical data, white papers and FDA documentation is up to date. We are the only solution that is over-the-counter approved for diabetic insulin, and approved for any subcutaneous liquid that a physician or dentist wants to prescribe. We have some European distribution channels opening and we wish to bring it to the American diabetes market for the 300,000 patients newly diagnosed every year. So many other drugs can use this technology, including hormone therapies, painkillers, vaccines and cancer drugs. We are ready to go now!

About Our Team

Creator: Dan Cohen

Location: Quebec

Bio: I have been involved in early stage science and technology ventures since 1995, helping to guide and fund more than 40 enterprises in life sciences, clean tech and information technology.

Title: VP Strategy

About Our Company

Inolife Technologies Inc.

Location: 300 Spectrum Center Drive
Irvine, CA 92618

Founded: 2013


Product Stage: Ready

YTD Sales: Less than $250,000

Employees: 5-10

How We Help Patients

  • No pain, no anxiety - no fear. Just a snapping noise in under one second and it's done.
  • Usable by a youth or adult with no training; can be administered by a technician or supervisor instead of a nurse or nurse practitioner, saving millions per year
  • No pain on injection (relieving the 20% of averse or phobic patients who avoid basic treatment)
  • No risk of deep bleeding, large bruises or other accidental damage of the surrounding tissue
  • Less expensive than others on the market, but codes also work for Medicare and Medicaid reimbursement
  • Drastic reduction in site contamination and infection (occurs in 6%-8% of injections)
  • Less lost drug product due to spillage or poor syringe technique
  • Can be administered virtually anywhere on the body (no “vein-hunting”)

How We Help Physicians

  • Can have professionals with minimal training administer the drugs (no nurse practitioner required)
  • No extensive sterilization or needle waste disposal costs
  • Drastically reduce returns due to injection site infections (currently 6%-8% of all injections)
  • Reduce patient anxiety and times for patient visit, especially in pediatrics
  • Can be administered virtually anywhere on the body (no “vein-hunting”)
  • Eliminates needle stick injuries that affect 2 million health care workers per year

How We Help Hospitals

  • No dangerous medical waste disposal, eliminating a cost of $30-$50 / liter / day for more than 6000 institutions in Canada/USA alone
  • Drastic reduction in site contamination and infection (occurs in 6%-8% of injections)
  • Creates great appeal for pain-free clinics (pediatric, dental…)
  • Similar costs and coverage as syringe-based regimen
  • Elimination of needlestick injuries and resulting staff downtime - 3000 occur in hospitals every day, with costs and damage ranging from $5000 per incident and absenteeism to massive claims
  • Device designed to be reused without sterilization
  • Compliance with sharps incidents requirements (federal and state law) are also greatly reduced

How We Help Partners

If you are a health insurance company, these are the benefits in working with us; 

  • Enables inexpensive home-based self-care
  • Improves adherence to drug regimens, better outcomes and reduced complications
  • Reduced incidence of site infection and return visits
  • Eliminates needlestick injuries and resulting staff insurance claims

If  you are a drug developer, whether you are an innovator, biosimilar or generic provider; 

  • Better adherence yields better outcome statistics
  • Less adjuvants and excipients results in lower costs per dose
  • Better tolerance than oral doses – reduced stomach ulcers, oral complications
  • Drastically lower dose costs in powder formulation (for our next generation product)
  • Co-packing opportunities can reduce medical errors in dosing, and risk of spoilage in handling
  • Possibility of extending patent life of key drugs – longer profit life - ask us about it!

Challenge Mission

Market Size

The market size for needle-free injectors has been carefully measured, and we use research reports from both Transparency (2014) and Zion Research (2015) to set the metrics. The market boundary is needle-free injections that are spring-loaded (versus battery powered or gas injected). North American suppliers produced 2.2 million units last year and growth is projected to be 14.6% CAGR for the next five years. This only tells part of the story; the consumable supply market grows more quickly, since the growth is in diabetes (multiple injections per day) and the increase in injectable drugs available, increasing by 35% in the next 5 years.

Projected 3 Year Growth

Projected 3 year growth is to distribute or donate 200,000 units in the United States, mostly in the diabetes market, with consumable supplies increasing to match the indication. This would bring the company to just under 10% of the market, a figure that the former company had already reached. An additional 20% of product sales will account for the international markets, using existing distributor agreements.

How We Will Make Money

Our revenue generation strategy is based on a smooth supply chain from the manufacturer to our distributors to the retail point of sales or clinical supply companies. The buyer's motivation is clear for the patient (avoiding pain and scarring), physician (time/reduced sharps), hospital (compliance) and insurance company (self care). Manufacturing, compliance and quality assurance are already in place with scalability to our 5-year projected targets. We have distribution agreements with 11 international organizations for the retail, clinical supply and hospital supply markets, as well as an online sales facility for the OTC product. Margins fluctuate depending on volumes, but in a classic "inkjet cartridge" model, the lifetime customer value is based on their use of the consumable products, whether the needle-free syringe or the disposable syringe. Margins for the device are between 35% and 45%, leaving a healthy space for the retailer while still keeping our price advantage. Margins or the consumables are in the 25% range and will continue to shrink with volume.

About our Competition

The competition in the United States is led by the J-Tip product by National Medical Products, currently holding over 70% of the market. However, the J-tip like most of the competitors (Zogenix, Antares, Glide, 3M and Pharmajet) is not meant for general use or available over the counter. The existing products are almost always found as co-marketed products with a specific drug - in the case of J-Tip, xylocaine, and for Pharmajet (one of the more visible companies), vaccine products. The market timing for a quality product available directly to the consumer is both unique and difficult to duplicate (FDA approval is required). Our own research, along with the Transparency and Zion collections, indicate strong opportunities for growth in all markets (both internationally and across disease indications).

Innovation Details

Intellectual Property Summary

We have licensed patent-protected material from our academic partners, but the bulk of the intellectual property lies in the devices used to manufacture the equipment. Since we have been granted equivalency status for other approved devices by the FDA, the barrier to entry is the extensive animal testing, clinical trials, quality assurance effort and comprehensive FDA filing process that we have completed already. 

Clinical Information

We have a library of clinical data that shows efficacy of drug delivery for this technology compared to syringe delivery, much of which has been published already. We will only need to perform equivalency trials for new drugs that we want to recommend, to establish that particular dosing and formulations have the same pharmacodynamics with this delivery mechanism. 

Regulatory Status

We have two FDA approvals; one to use the product for U-100 and equivalent insulin doses for type 2 diabetes, sold over the counter, and the second is for general purpose subcutaneous administration with a prescription. 

How we will use the funds raised

The funds will be used to get the product into the hands of diabetes care clinics, support groups, medical device writers and bloggers, patient associations, and veteran's care institutions so that the public opinion of the product can begin to take shape. There are a handful of needle-free technologies on the market today, but they are so tightly controlled and bound up with specific drug products that very few people know about them. There's no reason, in our opinion, for this technology to be kept out of the hands of every self-injecting diabetes patient and small clinic.

Thank You

If you know someone who hates needles - and most people do, even if they won't admit it - this is a gift. No anxiety, no pain, and no scarring. This has got to make the lives of your friends considerably easier. If you have friends who inject themselves daily (or multiple times), there might not be much you can do about their illness, but isn't this something you can do about their treatment? 



Login to post your comment!
Click here to Login


    No updates found .

Index Score




  • This campaign has ended but you can still get involved.
    See options below.

$ 500,000 goal